Elicio Therapeutics, Inc. Cash and Restricted Cash
Elicio Therapeutics, Inc. (ELTX) had Cash and Restricted Cash of $24.00 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $24.00M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15.65M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19.27M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $21.31M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $24.00M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $15.65M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $19.27M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $21.31M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $22.79M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $19.73M 10-Q · filed 2026-05-11 | |
| 2024-12-31 | $19.49M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $28.03M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $4.51M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $13.21M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $14.30M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $17.20M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $22.36M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $10.30M 10-Q · filed 2024-05-15 | $29.22M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $8.41M 10-K · filed 2025-03-31 | $50.49M 10-K · filed 2023-03-17 |
| 2022-09-30 | $4.61M 10-Q · filed 2023-11-13 | $55.14M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.22M 10-Q · filed 2023-08-14 | $63.37M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $73.00M 10-Q · filed 2023-05-10 | |
| 2021-12-31 | $10.04M 10-K · filed 2024-03-29 | $88.76M 10-K · filed 2022-03-30 |
| 2021-09-30 | $102.74M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $117.31M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $130.46M 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $34.61M 10-K · filed 2023-03-17 | |
| 2020-09-30 | $14.11M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $5.04M 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $987.00K 10-Q · filed 2021-05-17 | |
| 2019-12-31 | $5.57M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |